Back to search

Article

Compare HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate or tenofovir alafenamide fumarate

2022-02-22

Abstract excerpt

<title>Abstract</title> <p><bold>Background/purpose:</bold> Clinical relapse occurred majorly within the first six months after stopping tenofovir disoproxil fumarate (TDF) in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. However, the incidence and relapse pattern in patients stopping Tenofovir alafenamide fumarate (TAF), a prodrug of tenofovir which more concentrated in hepatocyte, i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9df49efa-8cfe-5ff4-a06d-ccb1ef7f9433
DOI
10.21203/rs.3.rs-1353362/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Compare HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate or tenofovir alafenamide fumarateDOI 10.21203/rs.3.rs-1353362/v1
Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.Semantic proximity
Sequential HBV Treatment With Tenofovir Alafenamide for Patients With Chronic Hepatitis B: Week 96 Results From a Real-world, Multicenter Cohort StudySemantic proximity
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.Semantic proximity
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antiviralsSemantic proximity
Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis BSemantic proximity
Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs.Semantic proximity
Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.Semantic proximity
The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.Semantic proximity
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.Semantic proximity
Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.Semantic proximity
Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV eliminationSemantic proximity
Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation.Semantic proximity
Select a neighboring publication to make it the new centre.